Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 2010 Apr 15;50(8):1192-7. doi: 10.1086/651419.

Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.

Author information

1
Department of Clinical Research and Biostatistics, Côte de Nacre University Hospital, Caen F-14033, France.

Abstract

Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication.

PMID:
20210643
PMCID:
PMC3591724
DOI:
10.1086/651419
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center